Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison
@article{Motaghi2019EtrolizumabVI, title={Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison}, author={E. Motaghi and Masoumeh Ghasemi-Pirbaluti and M. Zabihi}, journal={Pharmacological Research}, year={2019}, volume={139}, pages={120–125} }
Objectives: There is still a need to develop new effective medications for the treatment of ulcerative colitis, particularly for patients who are intolerant or resistant to first line therapies. This article compared the efficacy and safety of etrolizumab and infliximab in moderate to severe ulcerative colitis. Methods: This meta‐analysis was performed according to the PRISMA statement protocol. A systematic literature search of three major bibliographic databases (Scopus, PubMed, and Cochran… CONTINUE READING
Figures, Tables, and Topics from this paper
4 Citations
Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses
- Medicine
- United European gastroenterology journal
- 2019
- 9
Recent advances in inflammatory bowel disease therapy.
- Medicine
- European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
- 2020
References
SHOWING 1-10 OF 26 REFERENCES
An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
- Medicine
- Archives of medical science : AMS
- 2016
- 11
- Highly Influential
- PDF
Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs
- Medicine
- Expert review of gastroenterology & hepatology
- 2015
- 44
Etrolizumab for ulcerative colitis: the new kid on the block?
- Medicine
- Expert opinion on biological therapy
- 2016
- 5
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
- Medicine
- The Lancet
- 2014
- 303
- PDF
Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis
- Medicine
- PloS one
- 2016
- 59
- PDF
Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis
- Medicine
- Journal of clinical gastroenterology
- 2015
- 27
First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
- Medicine
- Journal of Gastroenterology
- 2015
- 61
- PDF
Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis.
- Medicine
- Mayo Clinic proceedings
- 2014
- 65
The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis Patients
- Medicine
- The American Journal of Gastroenterology
- 2007
- 148
Biologic agents for IBD: practical insights
- Medicine
- Nature Reviews Gastroenterology &Hepatology
- 2015
- 160
- Highly Influential